Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
A | 17.30 | 0.29% | 0.05 |
Earnings due: Nov 12
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
BB Squeeze Ended | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.29% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | 0.29% | |
Bollinger Band Squeeze | Range Contraction | 0.29% | |
Gapped Up | Strength | 0.29% | |
Overbought Stochastic | Strength | 0.29% | |
Fell Below 50 DMA | Bearish | 2.55% | |
20 DMA Support | Bullish | 2.55% |
Alert | Time |
---|---|
Gap Down Closed | about 21 hours ago |
Expansion Pivot Buy Entry | about 21 hours ago |
Rose Above Previous Day's High | about 21 hours ago |
Rose Above Upper Bollinger Band | about 21 hours ago |
Up 1% | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
Pieris Pharmaceuticals, Inc. Description
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Inflammatory Diseases Kidney Disease Dialysis Asthma Membrane Technology Sarcoma Carcinoma Hepatology Chronic Kidney Disease End Stage Renal Disease Kidney Renal Disease Blood Plasma Stage Renal Disease Central Nervous System Tumors Hepcidin Iron Deficiency
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 23.2 |
52 Week Low | 6.2 |
Average Volume | 12,446 |
200-Day Moving Average | 13.61 |
50-Day Moving Average | 16.93 |
20-Day Moving Average | 16.68 |
10-Day Moving Average | 16.95 |
Average True Range | 0.44 |
RSI (14) | 60.16 |
ADX | 7.86 |
+DI | 24.48 |
-DI | 20.91 |
Chandelier Exit (Long, 3 ATRs) | 16.15 |
Chandelier Exit (Short, 3 ATRs) | 17.35 |
Upper Bollinger Bands | 17.44 |
Lower Bollinger Band | 15.93 |
Percent B (%b) | 0.91 |
BandWidth | 9.01 |
MACD Line | 0.17 |
MACD Signal Line | 0.10 |
MACD Histogram | 0.0644 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 17.86 | ||||
Resistance 3 (R3) | 17.85 | 17.66 | 17.76 | ||
Resistance 2 (R2) | 17.66 | 17.52 | 17.66 | 17.73 | |
Resistance 1 (R1) | 17.48 | 17.43 | 17.57 | 17.49 | 17.70 |
Pivot Point | 17.29 | 17.29 | 17.34 | 17.29 | 17.29 |
Support 1 (S1) | 17.11 | 17.15 | 17.20 | 17.12 | 16.90 |
Support 2 (S2) | 16.92 | 17.06 | 16.92 | 16.87 | |
Support 3 (S3) | 16.74 | 16.92 | 16.84 | ||
Support 4 (S4) | 16.75 |